Psoriasis Treatment Market By Drug Class (TNF-Alpha Inhibitors, IL-17 Inhibitors, IL-12 and IL-23 Inhibitors, Retinoids), By Route of Administration (Topical, Oral, Injectable), By End-User (Hospitals, Clinics, Home Care Settings), By Distribution Channel (Direct Sales, Retail Pharmacies, Online Pharmacies), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Psoriasis Treatment Market was valued at USD 14.7 billion in 2024-e and will surpass USD 24.8 billion by 2030; growing at a CAGR of 9.2% during 2025 - 2030.

The psoriasis treatment market is experiencing steady growth, driven by the increasing prevalence of psoriasis, a chronic autoimmune condition that causes skin inflammation, redness, and the formation of scaly patches. This condition affects millions of people worldwide and significantly impacts patients' quality of life. As awareness of psoriasis increases, both patients and healthcare providers are seeking more effective treatments to manage symptoms, reduce flare-ups, and improve overall skin health. Advances in dermatology have paved the way for the development of innovative therapies, including biologics, oral medications, and topical treatments, which have improved treatment outcomes for psoriasis patients.

In recent years, biologic therapies targeting specific immune system pathways have revolutionized psoriasis treatment, offering significant benefits for patients with moderate to severe forms of the condition. These biologics, along with oral therapies and topical treatments, are becoming increasingly available through multiple distribution channels. The ongoing development of more targeted therapies and the growing understanding of psoriasis pathophysiology are expected to continue driving the market forward, expanding treatment options and enhancing patient care.

TNF-Alpha Inhibitors are Largest Drug Class Due to Proven Efficacy and Widespread Use

TNF-alpha inhibitors are the largest drug class in the psoriasis treatment market, owing to their proven efficacy in managing moderate to severe psoriasis. Tumor necrosis factor-alpha (TNF-alpha) is a key inflammatory cytokine involved in the pathogenesis of psoriasis, and inhibitors of this cytokine have been shown to significantly reduce inflammation, alleviate symptoms, and improve quality of life for psoriasis patients. Drugs like etanercept, infliximab, and adalimumab are well-established in the market and have been used for many years to treat psoriasis.

The widespread use of TNF-alpha inhibitors is largely attributed to their ability to provide long-term control over psoriasis symptoms and prevent disease progression. These biologics are effective in treating patients who have not responded to conventional therapies, offering relief from the persistent and often debilitating effects of psoriasis. Their proven track record, along with their availability in injectable forms, has solidified their position as the go-to treatment for many healthcare providers treating psoriasis.

IL-17 Inhibitors are Fastest Growing Drug Class Due to Targeted Action and Efficacy

IL-17 inhibitors are the fastest-growing drug class in the psoriasis treatment market, driven by their targeted mechanism of action and superior efficacy in treating psoriasis. Interleukin-17 (IL-17) is a pro-inflammatory cytokine that plays a crucial role in the pathogenesis of psoriasis by promoting the inflammatory cascade and stimulating keratinocyte proliferation. By inhibiting IL-17, these biologics help to reduce the inflammatory response and improve the skin condition of patients with moderate to severe psoriasis.

The rise of IL-17 inhibitors such as secukinumab and ixekizumab has significantly altered the treatment landscape for psoriasis, as these drugs offer a more precise approach to managing the disease compared to traditional treatments. With high efficacy, a favorable safety profile, and the ability to provide long-lasting relief, IL-17 inhibitors have become increasingly popular among healthcare providers and patients alike. As new IL-17 inhibitors enter the market, the segment is expected to experience rapid growth, further expanding treatment options for psoriasis patients.

Injectable Route of Administration is Fastest Growing Due to Advancements in Biologics

Injectable treatments represent the fastest-growing route of administration in the psoriasis treatment market, primarily driven by the rapid adoption of biologics and their ability to provide more effective and targeted relief. Injectable biologics, such as TNF-alpha inhibitors, IL-17 inhibitors, and IL-12/23 inhibitors, offer patients a way to manage moderate to severe psoriasis by targeting the immune system and modulating the inflammatory processes that lead to skin lesions. These biologics are typically administered subcutaneously or intravenously, offering more potent and long-lasting effects compared to topical treatments or oral medications.

The growth of injectable biologics is fueled by their effectiveness in controlling symptoms and reducing flare-ups in patients who do not respond to traditional therapies. As the market for biologic treatments expands, more innovative injectable options are being developed with improved safety profiles, offering patients better therapeutic outcomes and reduced frequency of injections. With the increasing preference for biologics in the treatment of psoriasis, injectable therapies are expected to dominate the market in the coming years.

Hospitals are Largest End-User Due to Specialized Care and Advanced Treatment Options

Hospitals are the largest end-users in the psoriasis treatment market, particularly for patients with moderate to severe psoriasis who require advanced treatment options. Hospitals are equipped with the necessary resources and medical professionals to administer injectable biologics and manage any side effects or complications associated with these therapies. Dermatologists and immunologists in hospital settings are often at the forefront of diagnosing and treating complex cases of psoriasis, offering specialized care and personalized treatment plans for each patient.

In addition to advanced biologic therapies, hospitals also offer a range of supportive care services, including phototherapy, systemic medications, and close monitoring of patients' progress. The presence of specialized clinics and multidisciplinary teams within hospitals makes them the preferred setting for managing more severe cases of psoriasis, ensuring patients receive the most comprehensive and effective care possible. As a result, hospitals are expected to continue to be the largest end-users of psoriasis treatments, particularly as biologic therapies become more widely available.

Retail Pharmacies are Largest Distribution Channel Due to Accessibility and Convenience

Retail pharmacies represent the largest distribution channel for psoriasis treatments, particularly for topical therapies and oral medications. Topical treatments, such as corticosteroids, vitamin D analogs, and moisturizers, are commonly available over-the-counter, making them easily accessible to patients for managing mild to moderate psoriasis symptoms. Additionally, oral medications such as acitretin and methotrexate are often prescribed to patients with less severe forms of psoriasis, and they are available at retail pharmacies, contributing to the growth of this distribution channel.

The increasing use of online pharmacies has further expanded access to psoriasis treatments, especially for patients who prefer the convenience of home delivery. With the ease of purchasing topical creams, over-the-counter medications, and even prescriptions through retail and online pharmacies, this distribution channel is expected to maintain its dominance in the psoriasis treatment market. As new treatments become available, both traditional and online retail pharmacies will play a critical role in delivering psoriasis therapies to patients worldwide.

North America Region is Largest Due to High Healthcare Access and Awareness

North America is the largest region in the psoriasis treatment market, driven by high healthcare access, awareness, and the availability of advanced treatment options. The United States, in particular, has a well-established healthcare infrastructure, providing patients with access to a broad range of psoriasis treatments, including biologics, oral medications, and topical therapies. The high rate of diagnosis and treatment for psoriasis in North America has resulted in a large and growing patient population seeking effective management options for the condition.

In addition to advanced medical facilities, North America benefits from strong research and development efforts in dermatology, which have led to the introduction of new and innovative therapies for psoriasis. The region’s focus on patient-centered care, coupled with increasing awareness and education about psoriasis, ensures that patients receive timely and effective treatments. As a result, North America is expected to remain the largest and most lucrative market for psoriasis treatments in the coming years.

Leading Companies and Competitive Landscape

The psoriasis treatment market is competitive, with several key players leading the development and commercialization of innovative therapies. Major companies such as AbbVie, Amgen, Novartis, Eli Lilly, and Janssen Biotech are prominent in the biologics segment, with their IL-17 inhibitors, TNF-alpha inhibitors, and IL-12/23 inhibitors playing a central role in the treatment of psoriasis. These companies are continuously investing in clinical trials and research to expand their product portfolios and improve the efficacy of their treatments.

The market is also seeing significant competition from smaller biotech firms and specialty pharmaceutical companies that are focusing on niche areas such as oral therapies, topical treatments, and the development of next-generation biologics. Partnerships, mergers, and acquisitions are common in this space as companies seek to expand their capabilities and reach in the psoriasis treatment market. As new therapies are developed and patient demand continues to grow, the competitive landscape will evolve, with companies focusing on innovation, improving patient outcomes, and addressing unmet needs in psoriasis care.

Recent Developments:

• In December 2024, AbbVie Inc. launched a new combination therapy for moderate-to-severe psoriasis, improving patient outcomes.
• In November 2024, Amgen Inc. announced new positive clinical trial results for its IL-17 inhibitor targeting psoriasis.
• In October 2024, Eli Lilly received FDA approval for its innovative biologic treatment for psoriasis, marking a breakthrough in patient care.
• In September 2024, Novartis International AG introduced an oral drug that offers significant improvement in psoriasis symptoms.
• In August 2024, Johnson & Johnson expanded its psoriasis treatment portfolio with a new topical formulation for localized plaque psoriasis.

List of Leading Companies:

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson
• Novartis International AG
• Pfizer Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb
• UCB S.A.
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Mylan N.V.
• Celgene Corporation
• Sanofi S.A.
• Dermira, Inc.
• Leo Pharma A/S

Report Scope: